Clinical Trials Browser

Triple Negative Breast Neoplasms × utomilumab × 90 days × Clear all

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms